CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$366,252 | -$153,610 | -$650,175 | $377,661 |
| Dep. & Amort. | $19,259 | $19,837 | $24,172 | $17,953 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $86,567 | $0 | $97,947 | $102,390 |
| Change in WC | $156,270 | -$193,585 | $19,845 | $26,859 |
| Other Non-Cash | -$38,618 | $66,983 | $12,470 | $14,109 |
| Operating Cash Flow | -$142,774 | -$260,375 | -$495,741 | $538,972 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,901 | -$9,470 | -$37,188 | -$81,705 |
| Net Acquisitions | $0 | $0 | $221,467 | $953,725 |
| Inv. Purchases | -$1,486,379 | -$1,065,911 | -$1,417,800 | -$1,509,327 |
| Inv. Sales/Matur. | $1,207,799 | $1,452,528 | $1,196,333 | $555,602 |
| Other Inv. Act. | $0 | -$2,500 | -$221,467 | -$953,725 |
| Investing Cash Flow | -$280,481 | $374,647 | -$258,655 | -$1,035,430 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $300,695 | $62,664 | $970 | $213,267 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $31,289 | $0 | $37,622 | $37,678 |
| Financing Cash Flow | $331,984 | $62,664 | $38,592 | $250,945 |
| Forex Effect | -$21 | $656 | -$80 | -$11 |
| Net Chg. in Cash | -$91,292 | $177,592 | -$715,884 | -$245,524 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $401,068 | $211,885 | $939,944 | $1,185,468 |
| End Cash | $309,776 | $389,477 | $224,060 | $939,944 |
| Free Cash Flow | -$144,675 | -$269,845 | -$532,929 | $457,267 |